Biofrontera about to crush it come January

Biofrontera Grows Revenues and Improves Financial Position in First Half 2017
Leverkusen, Germany, August 31, 2017 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer , today reported its financial results for the second quarter and first half ended June 30, 2017 and provided an update on recent operational and clinical developments.
“The first half of 2017 proved to be a great success as we grew our total revenues by 193% year-over-year to €5 million, driven primarily by our sales in the U.S. In the second quarter we took additional steps to further strengthen our momentum and improve the efficiency and effectiveness of our U.S. sales operations to drive adoption of Ameluz® by dermatologists. Additionally, as we seek to expand our market opportunity, we remain excited about the prospects for a basal cell carcinoma label extension with an efficient and less costly clinical development plan recently agreed upon with the FDA. In Europe, the approval from the European Commission for a label extension to include BCC reinforces our position in the PDT market and expands the reach of Ameluz® into hospitals where dermatologists are based in most countries in Europe. We also look forward to a positive opinion from the European Medicines Agency by the end of 2017 or early 2018 for our recently submitted application to expand the label of Ameluz® to include daylight-PDT. With the support of recent capital raises and the loan from the European Investment Bank, we believe that we have significant opportunities to continue to grow in all of our markets and expand our indications in order to support future growth,” commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera.
Second Quarter and First Half 2017 Financial Highlights:
• Sales increased by 193% to €5.0 million in H1 2017, compared to €1.7 million in the same period 2016.
• Generated €2.4 million in revenues in U.S. in H1 2017, in line with expectations.
• Research and development costs increased to €2.2 million in H1 2017 (up 18%), mainly due to costs incurred as part of the development partnership with Maruho.
• Net loss was €8.1 million in H1 2017

 

I wouldn't go that far to say they're crushing it, but no doubt the first half of next year could be big for Biofrontera.

Pent up frustration will mean a serious backlash - our customers are already talking about January and their new J code.

 

They made enough in 2017 to survive. In 2018 they will thrive because we jacked with our customers so much. How about another 40% increase in price? That will come back to bite us hard.

 

that's what I'm afraid of.
They're in the black and building momentum. Our price increases are killing stick volume and customers are going to seek revenge.

 

Microphone drop

 

Zero talent reps and management.

 

Dear Christoph:

What is happening in the field is not acceptable. PDT season is NOW. The field needs leadership, 2018 has been spent entirely putting out Holm/ Rose created fires. If not resolved quickly, the problem is on your watch. Biofrontera: where opportunities come to be squandered.

 

Not knowing PDT or US Buy/ Bill he will just continue to double down on his previous errors.

Tick, tock, tick, tock.......house is on fire

 

Which mistake?! Become a little more precise!!!!

I think there are currently rapidly gaining market share.

 

RE: Sun PDT sales rep or (the 7 still at that dumpster fire) looking for intel.

Please blog elsewhere and worry about your own business. Nothing to see here

 

We are now at the NASDAQ! A few more weeks and we overran you !!

BIOFRONTERA RULES!!!!!!!!

 

Objectively speaking, the spirit and culture at BF is what we thought we were going to have at SUN.

#prettycoolplacetobe

 

DW, get off cafepharma!

 

You got balls calling out an open position at Biofrontera.

Here's the funny thing: what's the turnover at SUN ? 40%, approaching 50% ? How long have territories been open at Sun ... 3,4,5 months !!! No one wants to join that company - word is out all over derm that it's a shit show.

Here's another one to stick in your hat:

Last night, Biofrontera posts a pic of their top performers (I'm assume at POA), and the two reps and manager awarded are all former SUN people. Holly and Katie are the top reps at SUN who defected to BF.

So while SUN posts company propaganda on social media sites in an attempt to mitigate its horrible reputation, and while they post multiple, multiple openings that have been vacant for months, BF posts beautiful pics and stories about their people, performers and "how they're treated like family" - per Holly.

Deliberate or not, that posted comment throws major shade on SUN.

Now, how about YOU get back to work filling all those multi-month vacancies at SUN.

 

Well, it looks like they sure called out your shit on that one !

 

You got balls calling out an open position at Biofrontera.

Here's the funny thing: what's the turnover at SUN ? 40%, approaching 50% ? How long have territories been open at Sun ... 3,4,5 months !!! No one wants to join that company - word is out all over derm that it's a shit show.

Here's another one to stick in your hat:

Last night, Biofrontera posts a pic of their top performers (I'm assume at POA), and the two reps and manager awarded are all former SUN people. Holly and Katie are the top reps at SUN who defected to BF.

So while SUN posts company propaganda on social media sites in an attempt to mitigate its horrible reputation, and while they post multiple, multiple openings that have been vacant for months, BF posts beautiful pics and stories about their people, performers and "how they're treated like family" - per Holly.

Deliberate or not, that posted comment throws major shade on SUN.

Now, how about YOU get back to work filling all those multi-month vacancies at SUN.

 

There is a reason there are so many positions open at BF.. good product, horrible leadership. No resources, no reimbursement help,

 

Typo:
You're talking about SUN, right ?

Y'all so messed up, it's funny watching you flailing around like fish outta water.

 

Obviously, you’re not having a real conversation with those who defected from Sun. The paycheck we got from Sun may not have been worth it, but the paycheck from Biofrontera isn’t worth it either. Biofrontera is shoveling the same crap, get off your Biofrontera pedestal.
Sell, sell off label, it’s not really a lie (ok maybe a little white lie) or should I say, a little blue and red one? Energy is energy.
Accounts not happy? Claims not getting paid, not even the Novitas ones? Don't worry about it— keep pushing them to buy more, who cares if they have 60 or 70 unpaid claims! Just throw in some “training tubes”
Oh and if you upset a customer that you’ve worked with for years, just go open 2 new ones, you can start deceiving them too.
Definitely don’t worry about the socialist quotas. 5 years experience, 4 months experience? Whatever... EVERYONE gets the same exact quota, that makes the most sense.
Bottom line— I may take home a little less money than I did before but I sleep better.

 

Biofrontera does not care about its customers!

Sales force/ RSM has been pleading with anyone that will listen, support is needed in field to support Market Access. 100% accurate and not an excuse. Dont even get me started on the Christoph equal goal distribution to sales, but what do do you expect? Jeff Holm has CD ear and top aid. 30+ years with zero track record, Jedi master-mind strategist at plagiarizing others work. How about the
dog-poo/ non scrubbed IMS data he rolled out to field?

CD + JH = We are in trouble! Not an opinion, that is bonafied fact.